MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
The Good Shroom Co Inc. (TSXV: MUSH) ("TGSC" or "the Company"), an emerging cannabis company with a focus on innovation, is ...
We recently published a list of Jim Cramer Discusses These 10 Stocks & President Trump’s Tariffs. In this article, we are ...